Segui
Filippo Pietrantonio
Filippo Pietrantonio
Affiliazione sconosciuta
Email verificata su istitutotumori.mi.it
Titolo
Citata da
Citata da
Anno
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis
F Pietrantonio, F Petrelli, A Coinu, M Di Bartolomeo, K Borgonovo, ...
European journal of cancer 51 (5), 587-594, 2015
5862015
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ...
Nature 552 (7683), 116-120, 2017
5482017
Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer
F Pietrantonio, R Miceli, A Raimondi, YW Kim, WK Kang, RE Langley, ...
Journal of Clinical Oncology 37 (35), 3392-3400, 2019
3502019
Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical …
C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ...
JAMA oncology 5 (3), 343-350, 2019
3392019
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with …
C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ...
The Lancet Oncology 21 (4), 497-507, 2020
2512020
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ...
Journal of the National Cancer Institute 109 (12), djx089, 2017
2302017
Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients
L Derosa, B Routy, M Fidelle, V Iebba, L Alla, E Pasolli, N Segata, ...
European urology 78 (2), 195-206, 2020
2202020
Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies
M Apicella, E Giannoni, S Fiore, KJ Ferrari, D Fernández-Pérez, C Isella, ...
Cell metabolism 28 (6), 848-865. e6, 2018
2142018
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
BO Van Emburgh, S Arena, G Siravegna, L Lazzari, G Crisafulli, G Corti, ...
Nature communications 7 (1), 13665, 2016
2022016
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ...
Annals of oncology 26 (10), 2092-2097, 2015
1952015
Targeting cancer metabolism: dietary and pharmacologic interventions
C Vernieri, S Casola, M Foiani, F Pietrantonio, F de Braud, V Longo
Cancer discovery 6 (12), 1315-1333, 2016
1722016
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer
F Pietrantonio, C Vernieri, G Siravegna, A Mennitto, R Berenato, ...
Clinical cancer research 23 (10), 2414-2422, 2017
1682017
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic …
R Moretto, C Cremolini, D Rossini, F Pietrantonio, F Battaglin, A Mennitto, ...
The oncologist 21 (8), 988-994, 2016
1382016
Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer
MP Roberti, S Yonekura, CPM Duong, M Picard, G Ferrere, M Tidjani Alou, ...
Nature medicine 26 (6), 919-931, 2020
1352020
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer
L Barault, A Amatu, FE Bleeker, C Moutinho, C Falcomatà, V Fiano, ...
Annals of oncology 26 (9), 1994-1999, 2015
1292015
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first …
G Fucà, V Guarini, C Antoniotti, F Morano, R Moretto, S Corallo, ...
British journal of cancer 123 (3), 403-409, 2020
1282020
Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis
F Petrelli, R Berenato, L Turati, A Mennitto, F Steccanella, M Caporale, ...
Journal of gastrointestinal oncology 8 (1), 148, 2017
1222017
Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review
D Baratti, S Kusamura, F Pietrantonio, M Guaglio, M Niger, M Deraco
Critical reviews in oncology/hematology 100, 209-222, 2016
1182016
HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research
F Pietrantonio, M Caporale, F Morano, M Scartozzi, A Gloghini, F De Vita, ...
International journal of cancer 139 (12), 2859-2864, 2016
1142016
Microsatellite instability in Gastric Cancer: Between lights and shadows
E Puliga, S Corso, F Pietrantonio, S Giordano
Cancer treatment reviews 95, 102175, 2021
1112021
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20